Tag Archives: treatment of pediatric chronic immune thrombocytopenic purpura

Novartis: European Commission (EC) approved Revolade® for treatment of pediatric chronic immune thrombocytopenic purpura (ITP) patients

EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily tablet and oral suspension formulation designed for younger children who may … Read the full press release